Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells

Nephrology Dialysis Transplantation

Volumn 31, Issue 11, 2016, Pages 1835-1845

  Fell, Lisa H ^a   Seiler Mußler, Sarah ^a   Sellier, Alexander B ^a   Rotter, Björn ^b   Winter, Peter ^b   Sester, Martina ^a   Fliser, Danilo ^a   Heine, Gunnar H ^a   Zawada, Adam M ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b GENXPRO GMBH   (Germany)

Author keywords

CKD; dendritic cells; immune deficiency; iron therapy; macrophages

Indexed keywords

CD141 ANTIGEN; CD163 ANTIGEN; CD1C ANTIGEN; CD40 ANTIGEN; CELL MARKER; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERROUS CHLORIDE; IRON ISOMALTOSE; IRON SACCHARATE; IRON SALT; MICRORNA; MICRORNA 146B 5P; MICRORNA 155 5P; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; DISACCHARIDE; FERRIC ION; FERRIC OXIDE, SACCHARATED; IRON DERIVATIVE; IRON ISOMALTOSIDE 1000; MALTOSE; SACCHARIC ACID;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL STIMULATION; CELL STRUCTURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DENDRITIC CELL; DRUG EFFECT; DRUG SPECIFICITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; IRON DEFICIENCY ANEMIA; IRON TRANSPORT; MACROPHAGE; MONOCYTE; PERITONEAL DIALYSIS; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; CASE CONTROL STUDY; CYTOLOGY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY;

ANEMIA, IRON-DEFICIENCY; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DENDRITIC CELLS; DISACCHARIDES; FERRIC COMPOUNDS; GLUCARIC ACID; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; MACROPHAGES; MALTOSE; MICRORNAS; MONOCYTES; PHAGOCYTOSIS;

EID: 84996487037     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw045     Document Type: Article

References (58)

1. Kidney Disease: Improving Global Outcomes. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
2. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
3. Andrews NC. Closing the iron gate. N Engl J Med 2012; 366: 376-377
4. CoyneDW, Kapoian T, SukiWet al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
5. Zitt E, Sturm G, Kronenberg F et al. Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS One 2014; 9: e114144
6. Agarwal R. Nonhematological benefits of iron. Am J Nephrol 2007; 27: 565-571
7. Winkelmayer WC, Mitani AA, Goldstein BA et al. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med 2014; 174: 699-707
8. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014; 29: 255-259
9. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
10. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis 2013; 7: 9-22
11. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
12. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 2012; 6: 43-51
13. Jahn MR, Andreasen HB, Futterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-491
14. Fell LH, Zawada AM, Rogacev KS et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014; 29: 809-822
15. Pai AB, Conner T, McQuade CRet al. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011; 24: 603-613
16. Serbina NV, Jia T, Hohl TM et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008; 26: 421-452
17. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010; 7: 77-86
18. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692
19. Martinez FO, Gordon S, Locati M et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303-7311
20. Zawada AM, Rogacev KS, Rotter B et al. SuperSAGE evidence for CD14+ +CD16+ monocytes as a third monocyte subset. Blood 2011; 118: e50-e61
21. Zawada AM, Rogacev KS, Muller S et al. Massive analysis of cDNA Ends (MACE) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease. Epigenetics 2014; 9: 161-172
22. Muller S, Rycak L, Winter P et al. omiRas: a web server for differential expression analysis of miRNAs derived from small RNA-Seq data. Bioinformatics 2013; 29: 2651-2652
23. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760
24. Wang L, Feng Z, Wang X et al. DEGseq: an R package for identifying differentially expressed genes fromRNA-seq data. Bioinformatics 2010; 26: 136-138
25. Davis M, Clarke S. Influence of microRNA on the maintenance of human iron metabolism. Nutrients 2013; 5: 2611-2628
26. O'Connell RM, Taganov KD, Boldin MP et al. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 2007; 104: 1604-1609
27. Vlachos IS, Kostoulas N, Vergoulis T et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012; 40: W498-W504
28. Paraskevopoulou MD, Georgakilas G, Kostoulas N et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res 2013; 41: W169-W173
29. Vlagopoulos PT, Tighiouart H,Weiner DE et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16: 3403-3410
30. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
31. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
32. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
33. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
34. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
35. Padhi S, Glen J, Pordes BA et al. Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ 2015; 350: h2258
36. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
37. Kamanna VS, Ganji SH, Shelkovnikov S et al. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012; 35: 114-119
38. Kuo KL, Hung SC, Lee TS et al. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014; 25: 2596-2606
39. Kartikasari AE, Visseren FL, Marx JJ et al. Intracellular labile iron promotes firm adhesion of human monocytes to endothelium under flow and transendothelial migration: iron and monocyte-endothelial cell interactions. Atherosclerosis 2009; 205: 369-375
40. Oexle H, Kaser A, Most J et al. Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells. J Leukoc Biol 2003; 74: 287-294
41. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723-737
42. Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol 2009; 21: 257-264
43. Taylor PR, Gordon S, Martinez-Pomares L. The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol 2005; 26: 104-110
44. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17: 593-623
45. Ichii H, Masuda Y, Hassanzadeh T et al. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50-57
46. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010; 116: e74-e80
47. Haniffa M, Shin A, Bigley V et al. Human tissues contain CD141hi crosspresenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37: 60-73
48. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-1260
49. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology 2013; 140: 22-30
50. Wong N,Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res 2015; 43: D146-D152
51. Andolfo I, Liguori L, De Antonellis P et al. The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro Oncol 2012; 14: 596-612
52. Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486
53. Schaar DG, Medina DJ, Moore DF et al. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol 2009; 37: 245-255
54. Chan SY, Zhang YY, Hemann C et al. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009; 10: 273-284
55. Yoshioka Y, Kosaka N, Ochiya T et al. Micromanaging iron homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J Biol Chem 2012; 287: 34110-34119
56. Futterer S, Andrusenko I, Kolb U et al. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 2013; 86: 151-160
57. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15(Suppl 2): S93-S98
58. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158